These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 28264846

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J.
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [Abstract] [Full Text] [Related]

  • 24. Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem.
    Zhang X, Wang Y, Li S, Xie F, Yi H.
    Antimicrob Agents Chemother; 2024 Mar 06; 68(3):e0154123. PubMed ID: 38319075
    [Abstract] [Full Text] [Related]

  • 25. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A.
    Eur J Clin Pharmacol; 2016 Jul 06; 72(7):839-48. PubMed ID: 27048201
    [Abstract] [Full Text] [Related]

  • 26. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA.
    Antimicrob Agents Chemother; 2005 Dec 06; 49(12):4920-7. PubMed ID: 16304153
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance.
    Jacobs A, Taccone FS, Roberts JA, Jacobs F, Cotton F, Wolff F, Creteur J, Vincent JL, Hites M.
    Antimicrob Agents Chemother; 2018 Sep 06; 62(9):. PubMed ID: 29987138
    [Abstract] [Full Text] [Related]

  • 29. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ, Kays MB, Mueller BA.
    J Clin Pharmacol; 2016 Oct 06; 56(10):1277-87. PubMed ID: 26919659
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R, Guidi M, Calpini V, Lamoth F, Decosterd L, Robatel C, Buclin T, Csajka C, Marchetti O.
    J Antimicrob Chemother; 2018 Dec 01; 73(12):3413-3422. PubMed ID: 30304491
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A, Canut A, Arribas J, Asín-Prieto E, Rodríguez-Gascón A.
    Eur J Clin Microbiol Infect Dis; 2016 Mar 01; 35(3):511-9. PubMed ID: 26782093
    [Abstract] [Full Text] [Related]

  • 34. Maximally effective dosing regimens of meropenem in patients with septic shock.
    Sjövall F, Alobaid AS, Wallis SC, Perner A, Lipman J, Roberts JA.
    J Antimicrob Chemother; 2018 Jan 01; 73(1):191-198. PubMed ID: 28961812
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.
    Zhao L, Li X, He X, Jian L.
    BMC Pharmacol Toxicol; 2020 Mar 04; 21(1):20. PubMed ID: 32131897
    [Abstract] [Full Text] [Related]

  • 39. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae.
    Sumi CD, Heffernan AJ, Naicker S, Islam K, Cottrell K, Wallis SC, Lipman J, Harris PNA, Sime FB, Roberts JA.
    J Antimicrob Chemother; 2020 Sep 01; 75(9):2633-2640. PubMed ID: 32585693
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.